Our results are also consistent with those published by Dahl et al. [30], Kajor et al. [38] and Krautbauer et al. [41] who demonstrated reduced visfatin and enhanced chemerin expression in the liver of individuals with hepatic steatosis and NASH compared to subjects with normal liver structure. This evidence concerns the gene RARRES2 and metabolic dysfunction-associated steatohepatitis.